ArticleScientific reports2023

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.

Toshihiko Matsumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.